Promega Corporation

ALK4 Kinase Enzyme System

See All Kinase Enzyme Systems
Recombinant human ALK4 (150–end) was expressed in Sf9 cells using an N-terminal GST tag. ALK4 is a member of the subfamily of receptor ser/thr kinases that mediates signaling by the Activins. ALK4 is expressed in many human tissues, including kidney, pancreas, brain, lung and liver. Truncated ALK4, predominantly expressed in human pituitary adenomas, function as dominant negative receptors to interfere with wild-type receptor function and blocks the antiproliferative effect of activin possibly contributing to development of human pituitary tumors (1). ALK4 is able to mediate Nodal ...

Expand to Read More »

  • Share
  • Print
  • Email
  • Prices valid for customers of Promega Brazil only
Product Size Conc. Catalog # *List Price Order QTY Add to Cart

ALK4 Kinase Enzyme System

Close Window

ALK4 Kinase Enzyme System

 Components

10μg
- V4508 Please Enquire

ALK4 Kinase Enzyme System

Close Window

ALK4 Kinase Enzyme System

 Components

1mg
- V6575 Please Enquire

ADP-Glo™ Kinase Assay + ALK4 Kinase Enzyme System

Close Window

ADP-Glo™ Kinase Assay + ALK4 Kinase Enzyme System

 Components

  • ALK4 Kinase Enzyme System

    V45081 x 10μg
  • ADP-Glo™ Kinase Assay

    V91011 x 1,000 assays
1 each
- V4509 Please Enquire


You Also May Be Interested In

Storage Conditions

Upon receipt, centrifuge the kinase and dispense it into smaller quantities. Store the kinase at –70°C and the rest of the components at –20°C.

For product intended use please see Patents & Disclaimers tab.

Use Restrictions

V4508, V6575, V4509 For Research Use Only. Not for Use in Diagnostic Procedures.

Patents - Disclaimers

V4509 U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

V4509 U.S. Pat. No. 7,700,310 and other patents and patents pending.

V4509 U.S. Pat. No. 7,741,067 and other patents and patents pending.

V4509 U.S. Pat. Nos. 6,602,677, 7,241,584 and 8,030,017 and other patents and patents pending.

V4509 U.S. Pat. No. 8,183,007 and other patents pending.

V4509 Licensed from Lonza Nottingham Ltd. under U.S. Pat. Nos. 6,599,711 and 6,911,319 and other pending and issued patents.

V4509 The method of recombinant expression of Coleoptera luciferase is covered by U.S. Pat. Nos. 5,583,024, 5,674,713 and 5,700,673.

Prefer a different language?

Your country is set to Brazil. Your language is set to Português. Please select the language that will best suit your needs:

This is correct, continue to site »

I need additional help

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.